Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, Russia. Dr. Misha V. Blagosklonny has then
Moved to America, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diverse biomedical topics, like targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author for a clinical phase I/II
Trial article.
After authoring seven papers during a brief yet fruitful
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to work with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Mikhail Blagosklonny published anumber of experimental research papers and theoretical articles as lead
Author. Those sole-author papers
Highlighted two important themes.
The first of these explained selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Verifying their resistance. The results and underlying
Notion were so revolutionary that they were improperly cited by
Other scientists as “reversal of resistance, ” even though the article was
Named, “Exploiting of drug resistance instead of its reversal. ” One great
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint publication in 2001.
The second topic throughout Dr. Blagosklonny’s sole-author articles
Is a research method to develop knowledge via
Bringing a few facts together from seemingly irrelevant fields.
This results in new notions containing testable forecasts, which in
Turn can be “tested” via analyzing the literature further. Once again, the
Notion was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Noticeable result discovered by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging medication, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others cannot even see. ”
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He agreed to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) via
Stopping organism aging — in other words, “preventing cancer
By staying young. ” His lab closely worked together with
Andrei Gudkov’s and conducted research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This resulted in the discovery of additional anti-aging
Medicines besides rapamycin. The cell culture studies were
Complemented by studies in mice, including several models such as
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
Dr. Mikhail Blagosklonny has also published extensively on the stoppage of cellular
Senescence by rapamycin as well as other mTOR inhibitors, life
Extension and cancer prevention in mice, and combinations of anti-
Aging medicines to be used in humans. A
Rapamycin-based combination of seven clinically available drugs has
Been named the “Koschei Formula” and is now utilized for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.
Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Mikhail V. Blagosklonny has then immigrated to the USA, where he was
Awarded the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Different biomedical topics, including targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer on a clinical phase I/II
Trial article.
After authoring seven papers within the period of a brief yet resulting
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to cooperate with Tito Fojo. Together, they
Published 26 papers. In addition, Dr. Misha Blagosklonny published a
Lot of experimental research papers and theoretical papers as lead
Author. The abovementioned sole-author papers
Discussed two important topics.
The first of those focused on selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Verifying their resistance. The outcomes and underlying
Concept were so revolutionary that they were incorrectly cited by
Other scientists as “reversal of resistance, ” even though the article was
Titled, “Exploiting of drug resistance instead of its reversal. ” One big
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint paper in 2001.
The second theme throughout Dr. Blagosklonny’s sole-author works
Is a research method to come up with knowledge by
Uniting several facts together from seemingly irrelevant fields.
This results in new notions with testable forecasts, which in
Turn can be “tested” by analyzing the literature further. Once again, the
Notion was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Important outcome discovered by Dr.Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging medication, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for
“connecting dots that others don' t even see. ”
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He decided to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
Since coming to Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Stopping organism aging — in other words, “preventing cancer
Via remainng young. ” His laboratory closely collaborated with
Andrei Gudkov’s and completed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of additional anti-aging
Medications besides rapamycin. The cell culture studies were
Complemented by studies in mice, including a few models such as
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
Dr. Misha Blagosklonny has also published extensively on the prevention of cellular
Senescence via rapamycin and other mTOR inhibitors, life
Prolongation and cancer prevention in mice, and combinations of anti-
Aging medicines to be used in humans. A
Rapamycin-based combination of seven clinically available medications has
Been named the “Koschei Formula” and is now utilized for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.
Страховая компания "ГАРМЕД" обеспечит максимально выгодные условия по страхованию частных и коммерческих рисков.
Виды страхования:
• транспортных рисков при перевозке грузов и пассажиров,
• рисков в строительстве и производстве,
• имущества физических и юридических лиц,
• втогражданской ответственности водителей,
• медицинское страхование.
Большой выбор условий страхования по любому из видов услуг, прозрачная процедуру урегулирования убытков – вот основные принципы нашей работы.
Самоклеящаяся защитная пленкадля метеллических поверхностей, это пленка предотвращающая металлические крашенные и полированные поверхности от механических повреждений во время производственного процесса, транспортировки и монтажа.
Защитная пленка используется на таких материалах как: полированный алюминий полированная нержавеющая сталь крашенная сталь анодированный алюминий крашеный алюминий
Области применения: производство столовых изделий; производтство алюминиевого профиля или его окраска; производтво строительных изделий из нержавеющей стали; производство бытовой техники (например, холодильники); производство сэндвич панелей; производство профнастила; производство кухонных вытяжек
При экструзиии, ламинации, покраске оконного алюминиевого и ПВХ профиля, используется самоклеящаяся защитная пленка для временной защиты поверхности. При использовании в линии экструзии, пленка надежно фиксируется к поверхности и удаляется только после монтажа.Самоклеящаяся защитная пленка обеспечивает полную защиту от любого повреждения, вызванного перевозкой, обработкой, монтажем. Применение защитной пленки гарантирует то что ваш продукт будет доставлен клиенту без повреждений. Защитная пленка для профиля, характеристики:
Толщина пленки 50 мкм Материал пленки полиэтилен высокого давления Клей акриловый на водной основе Клейкость слабая Возможность нанесения логотипа
